The content is available as a PDF (473.6 KB).
. 2022 Jun 16;162(7):S-279. doi: 10.1016/S0016-5085(22)60659-0
1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE
Alexander Xu
, Dalin Li
, Rebecca Elyanow
, Rachel M Gittelman
, Heidi Chapman
, John Prostko
, Valeriya Pozdnyakova
, Philip Debbas
, Angela Mujukian
, Arash A Horizon
, Kimia Sobhani
, Susan Cheng
, Ian M Kaplan
, Dermot PB Mcgovern
, Akil Merchant
, Gil Melmed
, Jonathan G Braun
Alexander Xu
Find articles by Alexander Xu
Dalin Li
Find articles by Dalin Li
Rebecca Elyanow
Find articles by Rebecca Elyanow
Rachel M Gittelman
Find articles by Rachel M Gittelman
Heidi Chapman
Find articles by Heidi Chapman
John Prostko
Find articles by John Prostko
Valeriya Pozdnyakova
Find articles by Valeriya Pozdnyakova
Philip Debbas
Find articles by Philip Debbas
Angela Mujukian
Find articles by Angela Mujukian
Arash A Horizon
Find articles by Arash A Horizon
Kimia Sobhani
Find articles by Kimia Sobhani
Susan Cheng
Find articles by Susan Cheng
Ian M Kaplan
Find articles by Ian M Kaplan
Dermot PB Mcgovern
Find articles by Dermot PB Mcgovern
Akil Merchant
Find articles by Akil Merchant
Gil Melmed
Find articles by Gil Melmed
Jonathan G Braun
Find articles by Jonathan G Braun
Issue date 2022 May.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9212302